Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening microangiopathy, frequently causing kidney failure. Inhibition of the terminal complement complex with eculizumab is the only licensed treatment but mostly requires long-term administration and risks severe side effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Klämbt, Verena, Gimpel, Charlotte, Bald, Martin, Gerken, Christopher, Billing, Heiko, Loos, Sebastian, Hansen, Matthias, König, Jens, Vinke, Tobias, Montoya, Carmen, Lange-Sperandio, Bärbel, Kirschstein, Martin, Hennies, Imke, Pohl, Martin, Häffner, Karsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815604/
https://www.ncbi.nlm.nih.gov/pubmed/32715379
http://dx.doi.org/10.1007/s00467-020-04714-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815604/
https://www.ncbi.nlm.nih.gov/pubmed/32715379
http://dx.doi.org/10.1007/s00467-020-04714-0

Ejemplares similares